Yang, Ning http://orcid.org/0000-0001-5121-7208
Garcia, Aitor http://orcid.org/0000-0002-6270-1369
Meyer, Cindy
Tuschl, Thomas
Merghoub, Taha
Wolchok, Jedd D.
Deng, Liang http://orcid.org/0000-0002-8467-9342
Funding for this research was provided by:
Society of Memorial Sloan Kettering
Ludwig Institute for Cancer Research (Ludwig Institute for Cancer Research)
Article History
Received: 21 March 2022
Accepted: 26 September 2022
First Online: 19 October 2022
Competing interests
: Memorial Sloan Kettering Cancer Center filed a patent application for the heat-inactivated vaccinia virus as a vaccine immune adjuvant. L.D., J.D.W., T.M., and N.Y. are authors on the patent, which has been licensed to IMVAQ Therapeutics. L.D., J.D.W., T.M., and N.Y. are co-founders of IMVAQ Therapeutics. T.M. is a consultant of Immunos Therapeutics and Pfizer. He has research support from Bristol Myers Squibb; Surface Oncology; Kyn Therapeutics; Infinity Pharmaceuticals, Inc.; Peregrine Pharmaceuticals, Inc.; Adaptive Biotechnologies; Leap Therapeutics, Inc.; and Aprea. He has patents on applications related to work on oncolytic viral therapy, alpha virus-based vaccine, neoantigen modeling, CD40, GITR, OX40, PD-1, and CTLA-4. J.D.W. is a consultant for Adaptive Biotech, Advaxis, Am-gen, Apricity, Array BioPharma, Ascentage Pharma, Astellas, Bayer, Beigene, Bristol Myers Squibb, Celgene, Chugai, Elucida, Eli Lilly, F Star, Genentech, Imvaq, Janssen, Kleo Pharma, Linnaeus, MedImmune, Merck, Neon Therapeutics, Ono, Polaris Pharma, Polynoma, Psioxus, Puretech, Recepta, Trieza, Sellas Life Sciences, Serametrix, Surface Oncology, and Syndax. Research support: Bristol Myers Squibb, Medimmune, Merck Pharmaceuticals, and Genentech. Equity: Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, Beigene, Trieza, and Linnaeus. Honorarium: Esanex. Patents: xenogeneic DNA vaccines, alphavirus replicon particles ex-pressing TRP2, MDSC assay, Newcastle disease viruses for cancer therapy, genomic signature to identify responders to ipilimumab in melanoma, engineered vaccinia viruses for cancer immunotherapy, anti-CD40 agonist mono-clonal antibody (mAb) fused to monophosphoryl lipid A (MPL) for cancer therapy, CAR T cells targeting differentiation antigens as means to treat cancer, anti-PD-1 antibody, anti-CTLA-4 antibodies, and anti-GITR antibodies and methods of use thereof.